Browse our anti-AZGP1 (AZGP1) Antibodies

Mouse (Murine) alpha-2-Glycoprotein 1, Zinc-Binding (AZGP1) interaction partners

1. Studied the novel role of zinc-alpha-2-glycoprotein (ZAG) in regulating hepatic steatosis, insulin resistance, and inflammation in the fatty liver in an obese mouse model.

2. A role of Azgp1 in lipid metabolism, in particular in mammary gland, during lactation.Azgp1 role in the expression of genes in the adipose tissue and liver.

3. ZAG may be beneficial for preventing high-fat-diet-induced hepatic lipid metabolic disorders.

4. Zinc alpha2 glycoprotein promotes browning in adipocytes.

5. AZGP1 is a negative regulator of fibrosis progression in kidney and heart

6. thyroid hormone up-regulates the production of zinc-alpha2-glycoprotein in the liver but not in the adipose tissue.

7. Overproduction of ZAG in white adipose tissue in chronic kidney disease could be a major contributor to metabolic disturbances associated with CKD.

8. Fatty acid synthase and hormone-sensitive lipase expression in liver are involved in zinc-alpha2-glycoprotein-induced body fat loss in obese mice.

9. ZAG synthesis in adipose tissue and the liver is downregulated, as are its circulating levels, in ob/ob mice.

10. Azgp1 is a possible candidate gene for regulation of body weight, elucidation of polygenic inheritance, and age-dependent changes in the genetic control of obesity.

11. Mice bearing the MAC16-tumor displayed substantial losses of body weight and fat mass, which was accompanied by major increases in ZAG mRNA and protein.

12. Glucocorticoids stimulate lipolysis through an increase in azgo1 expression, and they are responsible for the increase in azgp1 expression seen in adipose tissue of cachectic mice.

13. results suggest that EPA may preserve adipose tissue in cachectic mice by downregulation of ZAG expression through interference with glucocorticoid signalling

14. ZAG deficiency correlated with a significant decrease in adipocytic lipolysis

Human alpha-2-Glycoprotein 1, Zinc-Binding (AZGP1) interaction partners

1. In combination, proteins PRDX2 and ZAG yielded the highest discriminatory power (AUC=0.999), sensitivity (100%), and specificity (98.77%) in distinguishing the early stages of oral squamous cell carcinoma . The detection of PRDX-2 combining with ZAG protein could potentially be used as salivary biomarkers for early screening of OSCC.

2. High Zn-alpha-2-glycoprotein expression is associated with hyperthyroidism.

3. Circulating ZAG levels were significantly higher in patients with CS than in controls. ZAG levels positively correlated to 24-h urinary free cortisol, body mass index, non-esterified fatty acids, glucose, LDL-C, and type 2 diabetes mellitus, and were inversely related to total adiponectin levels.(p=0.035). In multivariate analysis ZAG levels only correlated with body mass index (p=0.012), type 2 diabetes mellitus.

4. Our study reveals that reduced AZGP1 expression correlates with in vitro cellular migration and invasion. In vivo, it is associated with higher metastatic risk and shorter survival in patients with soft tissue sarcomas

5. results indicate that changes in the circulating level of S100A1 protein occur in metabolic syndrome patients; the strong correlation between serum zinc-alpha2-glycoprotein and S100A1 might suggest that production or release of these two proteins could be related mechanistically

6. Study reports expression of Zinc-alpha2-glycoprotein (ZAG) in neurons. The level of ZAG was lower in temporal lobe epilepsy patients and time-dependently decreased in PTZ-treated rats. In addition, ZAG was shown to interact with p-ERK and TGF-beta. ZAG was found to be synthesized in neurons, and both the AZGP1 mRNA and ZAG protein levels were decreased in epilepsy patients and rat models.

7. Our study provides prospective phase III validation that absent/low AZGP1 expression provides independent prognostic value in PC

8. This study demonstrated that differential expression of zinc-alpha-2-glycoprotein (AZGP1) was detected in the serums of Alzheimer's Disease patients compared with healthy controls

9. ZAG has the potential to alleviate hepatosteatosis, making it a promising therapeutic target for fatty liver.

10. we found that AZGP1 inhibited cell migration and invasion through the regulation of the PTEN/Akt and CD44s pathways. Collectively, our findings revealed the molecular mechanism of AZGP1 expression in HCC, providing new insights into the mechanisms underlying tumor progression.

11. Absent or weak expression of AZGP1 protein was associated with worse recurrence free survival (RFS), disease specific survival, and overall survival after radical prostatectomy for prostate cancer.

12. Absent alpha-2-glycoprotein 1 zinc-binding(AZGP1) expression is an independent predictor of biochemical relapse in margin-positive localized prostate cancer and is associated with increased prostate cancer-specific mortality

13. Data show increased levels of lysozyme C (LYZ), lacritin (LACRT) and zinc-alpha-2 glycoprotein 1 (AZGP1) in pooled tear fluid sample from Graves' disease (GD) patients with moderate-to-severe Graves' orbitopathy (GO) compared with GD patients without clinical signs of GO.

14. From various categories of proteins that have been detected in prostate tissue by proteomics, only secreted protein Zinc alpha 2-glycoprotein showed a clear signal in the urine, proving its discriminative potential for the early diagnosis of prostate cancer

15. results indicate ZAG as a possible predictive marker of Gleason grade. The inverse association between grade and tissue expression with a rising serum protein level is similar to that seen with prostate-specific antigen. In addition, the results for both ZAG and PSMB-6 highlight the challenges in trying to associate the protein levels in serum with tissue expression

16. reduced AZGP1 expression is strongly related to adverse prostate cancer prognosis, independently of established clinic-pathological variables and PTEN deletions.

17. Zinc-alpha2-glycoprotein inhibits insulin-induced glucose uptake in human adipocytes by impairing insulin signaling at the level of AKT in a PP2A-dependent manner.

18. It was concluded that the lipid-binding groove in ZA2G contains at least two distinct fatty acid-binding sites.

19. AZGP1 is a negative regulator of fibrosis progression in kidney and heart

20. Plasma ZAG was elevated in smokers, and correlated with male gender, smoking amount and duration, nicotine dependence, and metabolic syndrome.

Cow (Bovine) alpha-2-Glycoprotein 1, Zinc-Binding (AZGP1) interaction partners

1. Polymorphisms in the AZGP1 gene were associated with growth traits.

2. association analysis of different genotypes with some of the growth and development traits